

S2 Table. Characteristics of patients with and without insulin and/or metformin exposure before the diagnosis of ER-negative breast cancer.

	No exposure to either drug (n=161)	Exposure to insulin (n=10)	Exposure to metformin (n=71)	Exposure to both drugs (n=28)	Total (n=270)	p-value
Histologic type						
IDC	137 (85.09)	6 (60.00)	60 (84.51)	20 (71.43)	223 (82.59)	0.209 ^{a)}
ILC	1 (0.62)	0	1 (1.41)	0	2 (0.74)	
Others	23 (14.29)	4 (40.00)	10 (14.08)	8 (28.57)	45 (16.67)	
Stage: T						
T0	0	0	1 (1.41)	0	1 (0.37)	0.148 ^{a)}
T1	60 (37.27)	4 (40.00)	24 (33.80)	7 (25.00)	95 (35.19)	
T2	77 (47.83)	2 (20.00)	31 (43.66)	10 (35.71)	120 (44.44)	
T3	6 (3.73)	2 (20.00)	7 (9.86)	5 (17.86)	20 (7.41)	
T4	3 (1.86)	0	1 (1.41)	0	4 (1.48)	
Tis	15 (9.32)	2 (20.00)	7 (9.86)	6 (21.43)	30 (11.11)	
Stage: N						
N0	100 (62.11)	7 (70.00)	45 (63.38)	18 (64.29)	170 (62.96)	0.771 ^{a)}
N1	39 (24.22)	1 (10.00)	16 (22.54)	5 (17.86)	61 (22.59)	
N2	12 (7.45)	1 (10.00)	3 (4.23)	4 (14.29)	20 (7.41)	
N3	10 (6.21)	1 (10.00)	7 (9.86)	1 (3.57)	19 (7.04)	
Stage: M						
M0	160 (99.38)	10 (100.00)	69 (97.18)	28 (100.00)	267 (98.89)	0.508 ^{b)}
M1	1 (0.62)	0	2 (2.82)	0	3 (1.11)	
PR						
Negative	158 (98.14)	10 (100.00)	71 (100.00)	27 (96.43)	266 (98.52)	0.386 ^{b)}
Positive	3 (1.86)	0	0	1 (3.57)	4 (1.48)	
Age at diagnosis (yr)						
< 40	14 (8.70)	0	2 (2.82)	0	16 (5.93)	0.023 ^{a)}
≥ 40 and < 50	29 (18.01)	0	7 (9.86)	1 (3.57)	37 (13.7)	
≥ 50	118 (73.29)	10 (100.00)	62 (87.32)	27 (96.43)	217 (80.37)	

CCI						
Mean±SD	5.76±2.19	6±3.53	6.32±2.18	7.04±2.13	6.05±2.27	0.012 ^{c)}
Median (min-max)	5 (1-16)	6.5 (1-12)	6 (1-12)	7.5 (3-11)	6 (1-16)	

Values are presented as number (%). CCI, Charlson comorbidity index; ER, estrogen receptor; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; M, metastasis; N, node; PR, progesterone receptor; SD, standard deviation; T, tumor. ^{a)}Chi-square test, ^{b)}Fisher exact test, ^{c)}Kruskal-Wallis test.